Legend Biotech

Legend Biotech Corp. is a holding company, which engages in the discovery and development of novel cell therapies for oncology and other indications. It operates through the North America and China geographical segments. The company was founded on May 27, 2015 and is headquartered in Somerset, NJ.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Legend Biotech surpasses Q2 sales targets, eyes market expansion

Legend Biotech's Q2 performance exceeded expectations with strong sales and positive study data.
The company's financial position is robust, with a healthy cash balance and plans for capacity expansion.
While facing challenges such as competitive pressures and operational optimizations, opportunities for growth exist.
Strategic initiatives focus on product quality, market expansion, and regulatory advancements for CARVYKTI.

Legend Biotech reports robust Q3 sales, eyes profitability targets

Legend Biotech's Q3 performance reflects strong sales driven by CARVYKTI, while maintaining a solid financial position with a focus on expansion.
The company faces challenges in achieving profitability targets and providing clarity on future sales projections.
Opportunities lie in pipeline advancements, collaboration partnerships, and innovative market expansion strategies.

Legend Biotech reports robust earnings, eyes expansion and regulatory milestones

Legend Biotech's strong earnings and cash balance provide stability and growth opportunities.
CARVYKTI's efficacy and convenience position it well, with plans for capacity expansion and partnerships.
Challenges include regulatory scrutiny and the need for clarity on future manufacturing scale-up.
Opportunities lie in extending manufacturing capacity, pipeline advancements, and profitability projections by 2026.

Legend Biotech reports robust Q1 performance and accelerates CAR-T expansion

Legend Biotech's Q1 2024 showcased strong performance with significant revenue growth and expansion plans to meet rising demand.
While facing challenges like sequential sales decrease and increased expenses, the company is leveraging strengths in production capacity and market diversification.
Opportunities lie in regulatory engagements for accelerated approvals, efficient market penetration strategies, and financial flexibility for future growth.
Overall, Legend Biotech's strategic focus on CAR-T therapies positions it well for continued success and innovation in the biopharmaceutical industry.

Legend Biotech excels in Q2, eyes FDA approvals and growth

Legend Biotech's Q2 2024 performance reflects strong sales growth, regulatory milestones, and promising clinical data, positioning the company for future success.
With a solid financial position, expanded production capacity, and ongoing research initiatives, Legend Biotech demonstrates resilience and strategic foresight in a competitive market landscape.
While facing challenges such as political risks and profitability targets, the company remains focused on growth opportunities and value creation for stakeholders.

Legend Biotech excels in Q3 with CARVYKTI growth and strategic advancements

Legend Biotech's Q3 performance reflects strong sales growth, regulatory milestones, and progress in clinical trials, underpinned by a robust balance sheet and strategic leadership appointments.
While challenges in outpatient treatment adoption and trial enrollment persist, the company's focus on innovation and operational excellence presents opportunities for future growth and market leadership.
Overall, Legend Biotech's solid financial standing, coupled with its expanding product portfolio and research capabilities, positions the company favorably for continued success and value creation for stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech announced third-quarter 2023 financial results.

Legend Biotech Reports Third Quarter 2023 Results and Recent Highlights

Johnson & Johnson

CVRx

Protagonist Therapeutics

J&J's biggest position is in a biotech that's developing cancer cell therapies. The healthcare giant's second-largest stake is in a medical device maker that focuses on heart failure.

Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that Legend Biotech Ireland Limited, a wholly owned subsidiary of Legend Biotech, has entered into an exclusive, global license agreement (License Agreement) with Novartis Pharma AG for certain Legend Biotech chimeric antigen receptor T-cell (CAR-T) cell therap.

Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3

Arcellx

Eyenovia

Gracell Biotechnologies

Let us look at a few biotech companies, ACLX, LEGN, GRCL and EYEN, which are poised to beat third-quarter earnings estimates.

4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, will host a conference call for investors at 8:00am Eastern Time on Monday, November 20, 2023, to review third-quarter results. Company executives will provide an overview of Legend Biotech's performance for the quarter. Investors and other interested parties may join the live.

Legend Biotech to Host Investor Conference Call on Third-Quarter Results

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech announces presentations to take place at the 65th American Society of Hematology Annual Meeting.

Legend Biotech to Showcase Leadership in Multiple Myeloma Treatment at the ASH 2023 Annual Meeting

Legend Biotech's Carvykti has shown improved uptake in the second quarter. The company aims to reach an annualized capacity of 10,000 doses of Carvykti by the end of 2025. Reaching the late 2025 goal would translate to quarterly net sales of nearly $1 billion by Q4 2025.

Legend Biotech: Working On Supply Issues

Legend Biotech Corporation (NASDAQ:LEGN ) Q2 2023 Earnings Conference Call August 15, 2023 8:00 AM ET Company Participants Jessie Yeung - Head of Investor Relations and Public Relations Ying Huang - Chief Executive Officer Lori Macomber - Chief Financial Officer Steve Gavel - Senior Vice President, Commercial Development, Us and Europe Guowei Fang - Chief Scientific Officer and Head of Business Development Conference Call Participants Kelly Shi - Jefferies Terence Flynn - Morgan Stanley Gena Wang - Barclays Umer Raffat - Evercore Yaron Werber - Cowen Kostas Biliouris - BMO Capital Justin Zelin - BTIG Mitchell Kapoor - H.C. Wainwright Brooke Schuster - William Blair Kelsey Goodwin - Guggenheim Operator Good morning and thank you for standing by.

Legend Biotech Corporation (LEGN) Q2 2023 Earnings Call Transcript

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech reported its unaudited financial results for the three and six months ended June 30, 2023.

Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights

Legend Biotech (LEGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Legend Biotech (LEGN)

Bill.com

On Holding AG

Walmart

We have narrowed our search to five stocks that are set to declare earnings results next week. These are: LEGN, TJX, WMT, ONON, BILL.

Top 5 Stocks Set to Beat on Earnings Next Week

CRISPR Therapeutics

Roivant Sciences Ltd

With everyone being an expert these days, the concept of top analyst biotech picks might seem suspect at first glance. While we depend on Wall Street's spectrum of expert guidance to establish a frame of reference, they can get some calls embarrassingly wrong.

3 Biotech Stocks That Analysts Are Drooling Over

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech will host a call to discuss second-quarter 2023 earnings on August 15, 2023 at 8:00am ET.

Legend Biotech to Host Investor Conference Call on Second-Quarter Results

Shares of Legend Biotech Corp. LEGN, -1.00% gained 3.7% premarket on Thursday after the company said its multiple myeloma therapy Carvykti, a collaboration with Johnson & Johnson JNJ, -0.20%, generated $117 million in sales in the second quarter. That represents a roughly 65% increase over the previous quarter, BMO Capital Markets analysts wrote in a research note Thursday, suggesting that the U.S. Food and Drug Administration has increased Carvykti's manufacturing cap.

Legend Biotech shares gain on multiple-myeloma drug sales

Legend's recently-leaked data showed Carvykti's prowess in earlier line MM patients. Analysts predict blockbuster potential in these earlier lines. Although looking expensive, there's potential for growth here on revenue expansion.

Despite High Share Price, Legend Bio Looks Like A Winner

Legend (LEGN) announces regulatory submission for expanded use of Carvykti to include adult patients with relapsed and lenalidomide-refractory multiple myeloma. Stock rises 4% following the news.

Legend (LEGN) Up 4% on sNDA Submission for Carvykti Expanded Use

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA).

Legend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Results from CARTITUDE-4 showed that cilta-cel reduced the risk of disease progression or death by 74% compared to SOC.

Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced it will participate in the upcoming investor conferences: Event: Jefferies Healthcare Conference Location: New York, NY Fireside Chat Date & Time: Wednesday, June 7, 2023 at 1:30pm ET Presenter: Ying Huang, Ph.D., CEO Event: Goldman Sachs 44th Annual Global.

Legend Biotech Announces Participation in Upcoming Investor Conferences

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech announced that a Type II variation application was submitted to EMA for CARVYKTI® based on data from the CARTITUDE-4 study.

Legend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today reported its first quarter 2023 unaudited financial results. "We are extremely pleased to announce that we have recently raised $762 million in funding. With this substantial capital infusion, we are poised to embark on a critical chapter in our company's growth to advan.

Legend Biotech Reports First Quarter 2023 Results and Recent Highlights

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech announces that new and updated data from the CARTITUDE program will be presented at the 2023 ASCO and EHA annual meetings.

Legend Biotech to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual Meetings

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced it will participate in the 2023 RBC Capital Markets Global Healthcare Conference in New York City. Ying Huang, PhD, CEO of Legend Biotech, will participate in a fireside chat on Wednesday, May 17, 2023 at 9:30 a.m. (Eastern Time). About Legend Biotech Legend Bi.

Legend Biotech Announces Participation in Upcoming Investor Conference

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that it has agreed to sell 5,468,750 American Depositary Shares (“ADSs”), each representing two ordinary shares of the Company, at a price of $64.00 per ADS, in a registered direct offering. The gross proceeds of the offering are expected to be approximately.

Legend Biotech Corporation Announces Pricing of Registered Direct Offering of $350 Million of American Depositary Shares

If everyone expects a stock to rise and buys it, eventually someone will be wrong. Legend Biotech's shares are up by quite a bit this year already.

News for Legend Biotech Stock (LEGN)